{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:29:46Z","timestamp":1777588186471,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":185,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.contraception.2020.01.011","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T02:24:11Z","timestamp":1580869451000},"page":"315-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7280-1171","authenticated-orcid":false,"given":"Laura J.","family":"Frye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Kilfedder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly","family":"Winikoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2020.01.011_b0005","series-title":"The package insert","first-page":"8","author":"Joseph","year":"2015"},{"key":"10.1016\/j.contraception.2020.01.011_b0010","unstructured":"Requirements on content and format of labeling for human prescription drug and biological products. vol. 21 CFR \u00a7201.56 2006. n.d."},{"key":"10.1016\/j.contraception.2020.01.011_b0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0968-8080(10)36534-7","article-title":"Self-induction of abortion among women in the United States","volume":"18","author":"Grossman","year":"2010","journal-title":"Reprod Health Matters"},{"key":"10.1016\/j.contraception.2020.01.011_b0020","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.contraception.2006.05.068","article-title":"Pharmacy provision of medical abortifacients in a Latin American city","volume":"74","author":"Lara","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.01.011_b0025","unstructured":"Wilson KS; Garcia SG; Lara D. Misoprostol use and its impact on measuring abortion incidence and morbidity. | POPLINE.org n.d. https:\/\/www.popline.org\/node\/216956 (accessed August 28, 2019)."},{"key":"10.1016\/j.contraception.2020.01.011_b0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.contraception.2017.09.007","article-title":"Developing a forward-looking agenda and methodologies for research of self-use of medical abortion","volume":"97","author":"Kapp","year":"2018","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.01.011_b0035","article-title":"Efficacy of misoprostol alone for first-trimester medical abortion: a systematic review","volume":"1","author":"Raymond","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2020.01.011_b0040","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/AOG.0b013e31818d8eb4","article-title":"Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial","volume":"112","author":"Winikoff","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2020.01.011_b0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.contraception.2011.12.012","article-title":"A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion","volume":"86","author":"Chong","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.01.011_b0050","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.contraception.2019.02.002","article-title":"Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial","volume":"99","author":"Sheldon","year":"2019","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.01.011_b0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.contraception.2010.05.013","article-title":"Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days\u2019 LMP: a randomized controlled trial","volume":"82","author":"Raghavan","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.01.011_b0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2008.09.001","article-title":"Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days\u2019 gestational age: a randomized controlled trial of sublingual and oral misoprostol","volume":"79","author":"Raghavan","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.01.011_b0065","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1471-0528.2010.02636.x","article-title":"Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial","volume":"117","author":"von Hertzen","year":"2010","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2020.01.011_b0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.contraception.2012.06.011","article-title":"First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review","volume":"87","author":"Raymond","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.01.011_b0075","unstructured":"WHO | Medical management of abortion. WHO 2019. http:\/\/www.who.int\/reproductivehealth\/publications\/medical-management-abortion\/en\/ (accessed March 20, 2019)."},{"key":"10.1016\/j.contraception.2020.01.011_b0080","unstructured":"Cervagem Pessaries. NPS Med n.d. https:\/\/www.nps.org.au\/medicine-finder\/cervagem-pessaries (accessed August 28, 2019)."},{"key":"10.1016\/j.contraception.2020.01.011_b0085","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJM199305273282101","article-title":"Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol","volume":"328","author":"Peyron","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2020.01.011_b0090","unstructured":"Mifeprex (Mifepristone) Information n.d."},{"key":"10.1016\/j.contraception.2020.01.011_b0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.contraception.2017.09.016","article-title":"Exploring the feasibility of obtaining mifepristone and misoprostol from the internet","volume":"97","author":"Murtagh","year":"2018","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.01.011_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112401","article-title":"Instability of misoprostol tablets stored outside the blister: a potential serious concern for clinical outcome in medical abortion","volume":"9","author":"Berard","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.contraception.2020.01.011_b0105","unstructured":"Quality of medicines: Quality of misoprostol products. WHO Drug Inf 2016;30."}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420300305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420300305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:10:56Z","timestamp":1762117856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782420300305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0010782420300305"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2020.01.011","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2020.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}